X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Biocon Ltd with Pfizer - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON LTD vs PFIZER - Comparison Results

BIOCON LTD    Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

PFIZER 
   Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON LTD PFIZER BIOCON LTD/
PFIZER
 
P/E (TTM) x 93.4 33.6 278.5% View Chart
P/BV x 7.6 5.0 152.7% View Chart
Dividend Yield % 0.2 0.8 21.5%  

Financials

 BIOCON LTD   PFIZER
EQUITY SHARE DATA
    BIOCON LTD
Mar-17
PFIZER
Mar-17
BIOCON LTD/
PFIZER
5-Yr Chart
Click to enlarge
High Rs1,1622,055 56.5%   
Low Rs4831,651 29.2%   
Sales per share (Unadj.) Rs194.6429.8 45.3%  
Earnings per share (Unadj.) Rs34.473.6 46.7%  
Cash flow per share (Unadj.) Rs48.387.4 55.2%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.11.1 11.3%  
Book value per share (Unadj.) Rs241.9528.7 45.7%  
Shares outstanding (eoy) m200.0045.75 437.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.24.3 98.0%   
Avg P/E ratio x23.925.2 94.9%  
P/CF ratio (eoy) x17.021.2 80.3%  
Price / Book Value ratio x3.43.5 97.0%  
Dividend payout %2.927.2 10.7%   
Avg Mkt Cap Rs m164,44084,777 194.0%   
No. of employees `0009.22.8 325.3%   
Total wages/salary Rs m7,4703,039 245.8%   
Avg. sales/employee Rs Th4,213.96,925.9 60.8%   
Avg. wages/employee Rs Th809.01,070.4 75.6%   
Avg. net profit/employee Rs Th745.21,186.3 62.8%   
INCOME DATA
Net Sales Rs m38,91119,663 197.9%  
Other income Rs m1,5711,012 155.3%   
Total revenues Rs m40,48220,674 195.8%   
Gross profit Rs m9,7953,491 280.6%  
Depreciation Rs m2,772629 440.5%   
Interest Rs m26010 2,708.3%   
Profit before tax Rs m8,3343,864 215.7%   
Minority Interest Rs m1630-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m01,304 0.0%   
Tax Rs m1,6161,801 89.7%   
Profit after tax Rs m6,8813,368 204.3%  
Gross profit margin %25.217.8 141.8%  
Effective tax rate %19.446.6 41.6%   
Net profit margin %17.717.1 103.2%  
BALANCE SHEET DATA
Current assets Rs m40,47720,789 194.7%   
Current liabilities Rs m16,7837,870 213.3%   
Net working cap to sales %60.965.7 92.7%  
Current ratio x2.42.6 91.3%  
Inventory Days Days6060 99.7%  
Debtors Days Days8322 369.5%  
Net fixed assets Rs m45,0739,175 491.2%   
Share capital Rs m1,000458 218.6%   
"Free" reserves Rs m47,37723,731 199.6%   
Net worth Rs m48,37724,189 200.0%   
Long term debt Rs m21,08225 84,328.0%   
Total assets Rs m93,94232,706 287.2%  
Interest coverage x33.1403.5 8.2%   
Debt to equity ratio x0.40 42,164.5%  
Sales to assets ratio x0.40.6 68.9%   
Return on assets %7.610.3 73.6%  
Return on equity %14.213.9 102.2%  
Return on capital %12.621.4 59.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,98863 20,648.6%   
Fx outflow Rs m7,8994,067 194.2%   
Net fx Rs m5,089-4,004 -127.1%   
CASH FLOW
From Operations Rs m6,4003,288 194.6%  
From Investments Rs m-4,985-2,496 199.7%  
From Financial Activity Rs m-1,775-826 214.9%  
Net Cashflow Rs m-473-35 1,367.1%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 63.9 32.2%  
Indian inst/Mut Fund % 8.4 7.5 112.0%  
FIIs % 10.7 4.9 218.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 23.7 84.0%  
Shareholders   109,995 85,207 129.1%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON LTD With:   MERCK LTD  CIPLA  ASTRAZENECA PHARMA  VENUS REMEDIES  STERLING BIOTECH  

Compare BIOCON LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens in Green; Pharma & Realty Stocks Gain(09:30 am)

Asian share markets are mixed today. The Nikkei 225 is flat while the Hang Seng is down 0.1%. The Shanghai Composite is trading down by 1.1%.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON LTD SHARE PRICE


Jun 20, 2018 10:53 AM

TRACK BIOCON LTD

  • Track your investment in BIOCON LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMPARE BIOCON LTD WITH

MARKET STATS